Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ChiCTR |
Last refreshed on:
|
3 July 2017 |
Main ID: |
ChiCTR-INR-17011829 |
Date of registration:
|
2017-07-02 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
Multiple center's clinical treatment of systemic onset juvenile idiopathic arthritis with tocilizumab
|
Scientific title:
|
Multiple center's clinical treatment of systemic onset juvenile idiopathic arthritis with tocilizumab |
Date of first enrolment:
|
2017-08-01 |
Target sample size:
|
Case:75;Control:75; |
Recruitment status: |
Pending |
URL:
|
http://www.chictr.org.cn/showproj.aspx?proj=20208 |
Study type:
|
Interventional study |
Study design:
|
Randomized parallel controlled trial
|
Phase:
|
New Treatment Measure Clinical Study
|
|
Countries of recruitment
|
China
| | | | | | | |
Contacts
|
Name:
|
Yang Jun
|
Address:
|
Shenzhen Children’s Hospital, 7019 Yitian Road, Shenzhen, China
518026
|
Telephone:
|
+86 18938690366 |
Email:
|
rogasansz@163.com |
Affiliation:
|
Shenzhen Children's Hospital |
|
Name:
|
Liang Fangfang
|
Address:
|
Shenzhen Children’s Hospital, 7019 Yitian Road, Shenzhen, China
518026
|
Telephone:
|
+86 18938690368 |
Email:
|
liangfangfang2008@163.com |
Affiliation:
|
Shenzhen Children's Hospital |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: 1. Pass the diagnosis standard of JIA from ILAR;
2. diagnosed as severe active period;
3. To be able to treated with appropriate glucocorticoid, MTX and/or NSAIDs, no other DMARDs allowed.
Exclusion criteria: 1) no latent diseases such as TB, HBV oe EBV;
2) no hypersensitivity to Tocilizumab or other accessories;
3) no macrophage activiation syndrome;
4) reject to sign the infromed consent;
5) participate in other clinical experiments simultaneously.
Age minimum:
Age maximum:
Gender:
Both
|
Health Condition(s) or Problem(s) studied
|
Systemic onset juvenile idiopathic arthritis
|
Intervention(s)
|
Case:Tocilizumab;Control:Conventional Treatment;
|
Primary Outcome(s)
|
IL-1;IL-6;IL-18;TNF-a;S100A8;S100A9;Index of joint pain;Index of joints swelling;Reheating time;ESR;CRP;SF;
|
Source(s) of Monetary Support
|
Health and Family Planning Commission of Shenzhen Municipality
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|